Stay updated on MRx0518 and Pembrolizumab Combo in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the MRx0518 and Pembrolizumab Combo in Solid Tumors Clinical Trial page.

Latest updates to the MRx0518 and Pembrolizumab Combo in Solid Tumors Clinical Trial page
- Check7 days agoChange DetectedRevision updated from v3.6.5 to v3.6.6, indicating a frontend deployment; no substantive study details are reflected in the visible content.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedRevision updated from v3.6.4 to v3.6.5, signaling a new edition of the page. This update appears to be a minor administrative change and does not alter the study details, eligibility criteria, or results.SummaryDifference0.1%

- Check42 days agoChange DetectedA new Revision: v3.6.4 was added. The previous Revision: v3.6.3 was removed.SummaryDifference0.1%

- Check63 days agoChange DetectedThe page metadata was updated to Revision: v3.6.3, replacing the previous Revision: v3.6.2.SummaryDifference0.1%

- Check71 days agoChange DetectedThe page's revision label was updated from v3.6.0 to v3.6.2, indicating a newer version of the study page is now in effect.SummaryDifference0.1%

- Check85 days agoChange DetectedRecruitment status now indicates the study is no longer enrolling participants. New user guidance pages and a refined Intervention/Treatment header were added to help users navigate and interpret the study details.SummaryDifference0.5%

Stay in the know with updates to MRx0518 and Pembrolizumab Combo in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MRx0518 and Pembrolizumab Combo in Solid Tumors Clinical Trial page.